ERBB2 and cancer: A llama anti-CD16 nanobody was fused to three different nanobodies targeting CD19, HER2, and EGFR cancer antigens to create anti-CD16/CD19, anti-CD16/HER2, and anti-CD16/EGFR BiKEs, respectively.